2026-01-22 - Analysis Report
**Eli Lilly (LLY) Stock Analysis**
=====================================

**Company Overview**
-------------------
Eli Lilly is a multinational pharmaceutical corporation.

**Return Rate Comparison**
------------------------

* Cumulative return of review stock (LLY): 281.03%
* Cumulative return of comparison stock (VOO): 91.55%
* Divergence: 173.60
* Relative divergence: 77.40%

The cumulative return of LLY stock is significantly higher than that of VOO, indicating a substantial outperformance.

**Alpha, Beta Analysis**
----------------------

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 37.0% | 14.3% | 32.0% | 0.7 | 103.7B |
| 2017-2019  | 36.0% | 14.7% | 19.0% | 0.7 | 117.8B |
| 2018-2020  | 30.0% | 20.9% | 9.0% | 0.7 | 151.4B |
| 2019-2021  | 49.0% | 20.9% | 5.0% | 0.7 | 247.6B |
| 2020-2022  | 59.0% | 20.9% | 60.0% | 0.7 | 328.0B |
| 2021-2023  | 116.0% | 18.0% | 115.0% | 0.5 | 522.6B |
| 2022-2024  | 123.0% | 27.0% | 104.0% | 0.6 | 692.1B |
| 2023-2025  | 183.0% | 29.9% | 121.0% | 0.7 | 963.4B |

LLY's historical returns exhibit high alpha values, indicating consistent outperformance relative to the market. Beta values remain relatively stable, indicating moderate risk exposure.

**Recent Stock Price Fluctuations**
--------------------------------

* Close: $1,078.52
* Last-market: $1,078.52 (previous close: $1,041.29, change: $3.58)
* 5-day SMA: $1,052.89
* 20-day SMA: $1,070.07
* 60-day SMA: $1,017.17

The stock price has shown a gentle rebound in recent days, but the 60-day SMA suggests a more significant uptrend.

**RSI, PPO Index Indicators**
-----------------------------

* Market Risk Indicator (MRI): 0.80 (High Investment Recommended)
* RSI: 49.77
* PPO: -0.50
* Hybrid Signal: Buy (Cash 0%)
* Risk Level: Medium (MRI 0.80)
* Recent (20 days) relative divergence change: -3.10 (-)
* 7-day Rank change: 2 (+)
* 7-day Dynamic Expected Return change: -1.20 (-)
* Expected Return (%): 57.10%

The stock is currently classified as medium risk, with a bearish RSI and PPO indicators. The expected return is relatively high, indicating potential long-term growth opportunities.

**Recent News & Significant Events**
-----------------------------------

The recent news headlines suggest increasing optimism about the company's prospects, with mentions of potential growth catalysts and positive analyst opinions.

**Analyst Opinions**
--------------------

* Analyst Consensus:
	+ Key: Buy
	+ Mean (1=StrongBuy~5=Sell): 1.70 (~Buy)
	+ Opinions: 28
	+ Target Price (avg/high/low): 1110.71 / 1500.00 / 770.00

The analyst consensus is overwhelmingly positive, with a mean rating of 1.70 and a target price range of $1,110.71 to $1,500.00.

**Recent Earnings Analysis**
---------------------------

| Date | EPS | Revenue |
|-----|-----|---------|
| 2025-10-30 | 6.22 | 17.60 B$ |
| 2025-08-07 | 6.3 | 15.56 B$ |
| 2025-05-01 | 3.07 | 12.73 B$ |
| 2024-10-30 | 1.08 | 11.44 B$ |
| 2025-10-30 | 1.08 | 11.44 B$ |

The company has reported consistent revenue growth and increasing profit margins in recent quarters.

**Financial Information**
------------------------

### Revenue and Profitability

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.60B | 82.91% |
| 2025-06-30 | $15.56B | 84.27% |
| 2025-03-31 | $12.73B | 82.53% |
| 2024-12-31 | $13.53B | 82.24% |
| 2024-09-30 | $11.44B | 81.02% |

LLY's revenue and profit margins have consistently improved in recent quarters, indicating strong operational performance.

### Capital and Profitability

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $23.79B | 23.46% |
| 2025-06-30 | $18.27B | 30.98% |
| 2025-03-31 | $15.76B | 17.50% |
| 2024-12-31 | $14.19B | 31.07% |
| 2024-09-30 | $14.24B | 6.81% |

The company's equity balance has increased in recent quarters, and the return on equity (ROE) has consistently improved, indicating strong profitability.

**Comprehensive Analysis**
-------------------------

LLY's stock has exhibited exceptional performance in recent years, with high alpha values and stable beta levels. The company's financials have shown consistent revenue growth and increasing profit margins. Analysts are overwhelmingly positive, with a consensus rating of 1.70 and a target price range of $1,110.71 to $1,500.00. While the RSI and PPO indicators are bearish, the MRI is classified as high-risk, indicating potential opportunities for long-term growth investors.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.